A carregar...
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes
Outcome in patients with myelodysplastic syndrome (MDS) after azanucleoside failure is poor with unmet need for active novel agents. Preclinical data have suggested that erlotinib has in vivo and in vitro off epidermal growth factor receptor (EGFR)-target activity in MDS. We conducted a phase II stu...
Na minha lista:
| Publicado no: | Am J Hematol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4561860/ https://ncbi.nlm.nih.gov/pubmed/24764152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23749 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|